Print

Oncology remains hot area for deal making as CNS shows a surge

Date August 03, 2011

Considering the enthusiastic scramble into oncology by both big and small drug developers over the last few years it is no revelation that the therapy area chalked up more licensing deals than any other last year. According to an analysis of EvaluatePharma data, deals over 154 cancer products were struck in 2010.

What is more of a surprise is the seeming rebound in the popularity of therapies that act on the central nervous system – after three straight years of declines, 149 of these agents were licensed in 2010, 39% more than in 2009 and the first year in which the therapy area has come close to oncology in terms of deal activity. Signs are these two fields of research are set to remain hot areas for deal making – according to EvaluatePharma’s Partnering Opportunities there are more candidates available for licensing in these two therapy areas than all other areas put together (see tables).

This content is written, edited and published by EP Vantage and is distributed by Evaluate Ltd. All queries regarding the content should be directed to: news@epvantage.com

EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.

Drawing on Evaluate, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.

EP Vantage SM ©2014 EP Vantage Ltd